Scientific Advisory Board

ContraVir leadership brings deep experience in the development and commercialization of targeted antiviral therapies for indications of important unmet need.

Carol L. Brosgart, M.D.

Chair, Scientific Advisory Board

Carol Brosgart, M.D., serves as Special Adviser on Health Care for FIPRA International and as a consultant to biotechnology companies. She is a Clinical Professor of Medicine in the Divisions of Global Health Sciences, Biostatistics and Epidemiology in the Department of Medicine at the University of California, San Francisco (UCSF). From 2011 through 2013, she served as the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the Centers for Disease Control and to the Viral Hepatitis Action Coalition at the CDC Foundation. Learn More >>

Jordan Feld, M.D., M.P.H

Scientific Advisory Board

Dr. Feld is an internationally recognized clinical and laboratory researcher in viral hepatitis. He is an Assistant Professor of Medicine at the University of Toronto and a clinician-scientist based at the Toronto Western Hospital Liver Center and the McLaughlin-Rotman Centre for Global Health. His laboratory work focuses on understanding treatment non-response in hepatitis C infection and more broadly on understanding the antiviral immune response with the goal of developing new strategies for the treatment of viral hepatitis. Learn More >>

Philippe Gallay, Ph.D.

Scientific Advisory Board

Dr. Gallay is Professor, Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla (San Diego), California. Dr. Gallay holds a Swiss Federal Diploma (MS), from the Institute of Biochemistry, Epalinges, Switzerland and a PhD from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.  Dr. Gallay’s research program examines the molecular basis of HIV, HCV, and HBV pathogenesis, including characterization of host proteins modulating viral replication, such as various cyclophilins (Host Targeting Antivirals). Learn More >>

Jörg Petersen, M.D, Ph.D.

Scientific Advisory Board

Dr. Petersen is a Professor of Medicine and Head of the Liver Unit at the IFI Institute for Interdisciplinary Medicine at the Asklepios Klinik St. George, University of Hamburg, Germany. He received his clinical training at the University of Hamburg, Mount Sinai Medical School, New York, USA, Tulane Medical School, Louisiana, USA and University of Zurich, Switzerland. He is board certified in Internal Medicine, Gastroenterology and Infectious diseases. Dr. Petersen was a research fellow for several years with grant support from the German Research Foundation and the NIH. Learn More >>

Fabien Zoulim, M.D., Ph.D.

Scientific Advisory Board

Dr. Zoulim is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and ANRS, and in different national and international committees. Learn More >>

Nikolai V. Naoumov, M.D., Ph.D.

Scientific Advisory Board

Nikolai Naoumov works at Novartis Global Drug Development, based in Basel, Switzerland. His focus is on developing new therapies for patients with liver diseases such as NASH, autoimmune diseases, liver fibrosis and complications of cirrhosis, closely interacting with clinical and research teams.  In addition to his work at Novartis Global, Nikolai is also Honorary Professor of Hepatology, University College London and Honorary Scientific Advisor to the Foundation for Liver Research in the UK. Learn More >>

Jin-Lin Hou, M.D.

Scientific Advisory Board

Professor Jin-Lin Hou is the Director and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, China. Previously, Professor Hou served as President of the Chinese Medical Association of Infectious Diseases, as well as President of APASL 2017. He has been invited to deliver talks at both national and international liver conferences owing to his expertise in viral hepatitis. His research interests include the clinical management of viral hepatitis and the molecular virology and immunology of hepatitis B virus. Learn More >>

Henry Lik Yuen Chan, M.D., FRCP, FAASLD, FHKCP, FHKAM, MBCHB

Scientific Advisory Board

Professor Henry Lik Yuen Chan is currently Head of Division of Gastroenterology and Hepatology, Director of Institute of Digestive Disease, Director of Center for Liver Health, Director of Office of Global Engagement, and Assistant Dean (External Affairs) of Faculty of Medicine, The Chinese University of Hong Kong. Professor Chan is a key investigator in over 30 international trials on antiviral treatment of chronic hepatitis B and C, and is the global lead author in publications on tenofovir disoproxil fumarate and tenofovir alafenamide for the treatment of viral hepatitis B. Learn More >>